BibTex RIS Cite

Gleason skoru 3+4 ve 4+3 prostat kanseri olgularında preoperatif klinikopatolojik ve radyografik bulguların karşılaştırılması

Year 2011, Volume: 6 Issue: 3, 6 - 10, 01.08.2011

Abstract

Amaç: Bu çalışmada prostat spesifik antijen PSA yüksekliği ve anormal rektal muayene bulgusu nedeniyle transrektal ultrasonografi TRUSG eşliğinde prostat biyopsisi alınan olgularda, biyopsi spesmenindeki gleason skoru 3+4 olan olgularla, 4+3 olan olguların preoperatif klinikopatolojik ve radyografik bulgularını karşılaştırmayı amaçladık. Gereç ve Yöntem: Kliniğimizde 2004-2011 yılları arasında PSA yüksekliği ve anormal rektal muayene bulgusu nedeniyle TRUSG eşliğinde 10 kadran prostat biyopsisi alınan 1135 olgudan, patolojisi prostat adenokarsinomu olarak raporlanan ve gleason skoru 3+4 olan 56 hasta Grup 1 ile gleason skoru 4+3 olan 48 hasta Grup 2 çalışmaya dahil edildi. Her iki gruptaki olgular yaş, total PSA, PSA dansitesi, ortalama prostat volümü, pozitif kor yüzdesi, pozitif kor yüzdesinin ≥ %33 olması, pozitif korlardaki en yüksek tümör yüzdesinin ortalaması, perinöral invazyon, rektal muayene ve tomografik bulgular açısından karşılaştırıldı. Bulgular: Grup 1 ve Grup 2’deki olgular karşılaştırıldığında yaş, ortalama prostat volümü, total PSA, PSA dansitesi, pozitif kor yüzdesi, pozitif kor yüzdesinin ≥ %33 olması, perinöral invazyon, rektal muayene ve tomografik bulgular açısından fark saptanmadı. Pozitif korlardaki en yüksek tümör yüzdesinin ortalaması Grup 1’de %69.60 ± 25.31 ve Grup 2’de %86.55 ±17.68 olarak bulundu ve gleason skoru 4+3 olan grupta istatistiksel olarak anlamlı oranda yüksekti p

References

  • Boyle P, Dresler C. Preventing the lung cancer epidemic. Ann Oncol. 2005 Oct; 16(10):1565-6.
  • Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin. 2008 Mar- Apr;58(2):71-96.
  • Dinçel Ç. Üroonkoloji, Prostat kanserinde biyopsi. 1.Baskı. İzmir, Meta Basım Matbaacılık, 2007, p 45.
  • Hodge KK, McNeal JE, Terris MK, Stamey TA. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol1989;142(1):71-74; dis- cussion 74-75
  • Gleason DF. Classification of prostatic carcinomas. Cancer Chemother Rep 1966;50:125-8.
  • Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL.ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pat- hol 2005;29:1228-42.
  • Axel Heidenreich , Gunnar Aus , Michel Bolla , Steven Jo- niau, Vsevolod B. Matveev , Hans Peter Schmid , Filliber- to Zattoni EAU Guidelines on Prostate Cancer 2010 p11.
  • Chan TY, Partin AW, Walsh PC, Epstein JI. Prognos- tic significance of Gleason score 3+4 versus Gleason sco- re 4+3 tumor at radical prostatectomy. Urology. 2000 Nov 1;56(5):823-7
  • Makarov DV, Sanderson H, Partin AW, Epstein JI. Glea- son score 7 prostate cancer on needle biopsy: is the prog- nostic difference in Gleason scores 4 + 3 and 3 + 4 inde- pendent of the number of involved cores? J Urol. 2002 Jun;167(6):2440-42
  • Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer sta- ging nomograms (Partin Tables) for the new millennium. Urology. 2001 Dec;58(6):843-8
  • Nelson CP, Rubin MA, Strawderman M, Montie JE, Sanda MG. Preoperative parameters for predicting early prosta- te cancer recurrence after radical prostatectomy. Urology. 2002;59:740–745.
  • Gretzer MB, Epstein JI, Pound CR, Walsh PC, Partin AW. SubstratiŞcation of Stage T1C prostate cancer based on the probability of biochemical recurrence. Urology. 2002;60:1034–1039.
  • Dall’Era, M.A., et al., Active surveillance for the manage- ment of prostate cancer in a contemporary cohort. Cancer, 2008. 112(12): p. 2664-70.
  • Herman CM, Kattan MW, Ohori M, Scardino PT, Whee- ler TM. Primary Gleason pattern as a predictor of disease progression in gleason score 7 prostate cancer: a multivari- ate analysis of 823 men treated with radical prostatectomy. Am J Surg Pathol. 2001 May;25(5):657-60.
  • Lau WK, Blute ML, Bostwick DG, Weaver AL, Sebo TJ, Zincke H. Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: differences in outcome between primary Gleason grades 3 and 4. J Urol. 2001 Nov;166(5):1692-7.
  • Rasiah KK, Stricker PD, Haynes AM, Delprado W, Turner JJ, Golovsky D, Brenner PC, Kooner R, O’Neill GF, Grygi- el JJ, Sutherland RL, Henshall SM. Prognostic significance of Gleason pattern in patients with Gleason score 7 prosta- te carcinoma. Cancer. 2003 Dec 15;98(12):2560-5.
  • Wright JL, Salinas CA, Lin DW, Kolb S, Koopmeiners J, Feng Z, Stanford JL. Prostate cancer specific mortality and Gleason 7 disease differences in prostate cancer out- comes between cases with Gleason 4 + 3 and Gleason 3 + 4 tumors in a population based cohort. J Urol. 2009 Dec;182(6):2702-7.
  • Epstein JI. Gleason score 2-4 adenocarcinoma of the pros- tate on needle biopsy: a diagnosis that should not be made. Am J Surg Pathol. 2000 Apr;24(4):477-8.
  • Stark JR, Perner S, Stampfer MJ, Sinnott JA, Finn S, Eisens- tein AS, Ma J, Fiorentino M, Kurth T, Loda M, Giovan- nucci EL, Rubin MA, Mucci LA. Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol. 2009 Jul 20;27(21):3459-64.
  • Masieri L, Lanciotti M, Nesi G, Lanzi F, Tosi N, Minervi- ni A, Lapini A, Carini M, Serni S. Prognostic role of pe- rineural invasion in 239 consecutive patients with pat- hologically organ-confined prostate cancer. Urol Int. 2010;85(4):396-400.
  • Loeb S, Epstein JI, Humphreys EB, Walsh PC. Does perine- ural invasion on prostate biopsy predict adverse prostatec- tomy outcomes? BJU Int. 2010 Jun;105(11):1510-3.
  • A. Heidenreich (chairman), M. Bolla, S. Joniau,M.D. Ma- son, V. Matveev, N. Mottet, H-P. Schmid,T.H. van der Kwast, T. Wiegel, F. Zattoni. Guidelines on Prostate Can- cer. European Association of Urology 2011 p.28
  • Stephan C, Klaas M, Müller C, Schnorr D, Loening SA, Jung K Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update. Clin Chem. 2006 Jan;52(1):59-64.
  • Hara R, Jo Y, Fujii T, Kondo N, Yokoyoma T, Miyaji Y, Na- gai A. Optimal approach for prostate cancer detection as initial biopsy: prospective randomized study comparing transperineal versus transrectal systematic 12-core biopsy. Urology. 2008 Feb;71(2):191-5.
  • Takenaka A, Hara R, Ishimura T, Fujii T, Jo Y, Nagai A, Fujisawa M. A prospective randomized comparison of diagnostic efficacy between transperineal and transrec- tal 12-core prostate biopsy. Prostate Cancer Prostatic Dis. 2008;11(2):134-8.
  • Epstein JI, Herawi M. Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicio- us for carcinoma: implications for patient care. J Urol. 2006 Mar;175(3 Pt 1):820-34.

Comparison of preoperative clinicopathological and radiographical findings between prostate cancer cases with gleason score 3+4 and 4+3

Year 2011, Volume: 6 Issue: 3, 6 - 10, 01.08.2011

Abstract

Objective: In this study, our objective was to compare the preoperative clinicopathological and radiographical findings of prostate cancer cases with gleason score 3+4 and 4+3 diagnosed by transrectal ultrasonography TRUSG guided biopsy. Materials and Methods: A total of 1135 patients underwent 10-quadrant TRUSG guide prostate biopsy because of high PSA values or abnormal digital rectal examination in our clinic between 2004-2011. Of those patients who had adenocarcinoma were divided into 2 groups of Gleason score 3+4 Group 1, 56 patients and Gleason score 4+3 Group 2, 48 patients . These two groups were compared in terms of age, total PSA, PSA density, mean prostate size, positive core percentage, a positive core value of 33% or more, mean highest positive core tumor percentage, perineural invasion, rectal examination and tomography findings. Results: Both groups are compared clinical, pathological and in terms of tomographical findings preoperatively. In this comparison, there was no difference in terms of age, total PSA, PSA density; mean prostate volume, positive core percentage, a positive core value of 33% or more, perineural invasion, rectal examination and tomography findings. The mean highest positive core tumor percentage was %69.60 ± 25.31 in group 1 and %86.55 ±17.68 in group 2. The mean highest positive core tumor percentage was significantly higher in the group 2 p

References

  • Boyle P, Dresler C. Preventing the lung cancer epidemic. Ann Oncol. 2005 Oct; 16(10):1565-6.
  • Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin. 2008 Mar- Apr;58(2):71-96.
  • Dinçel Ç. Üroonkoloji, Prostat kanserinde biyopsi. 1.Baskı. İzmir, Meta Basım Matbaacılık, 2007, p 45.
  • Hodge KK, McNeal JE, Terris MK, Stamey TA. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol1989;142(1):71-74; dis- cussion 74-75
  • Gleason DF. Classification of prostatic carcinomas. Cancer Chemother Rep 1966;50:125-8.
  • Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL.ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pat- hol 2005;29:1228-42.
  • Axel Heidenreich , Gunnar Aus , Michel Bolla , Steven Jo- niau, Vsevolod B. Matveev , Hans Peter Schmid , Filliber- to Zattoni EAU Guidelines on Prostate Cancer 2010 p11.
  • Chan TY, Partin AW, Walsh PC, Epstein JI. Prognos- tic significance of Gleason score 3+4 versus Gleason sco- re 4+3 tumor at radical prostatectomy. Urology. 2000 Nov 1;56(5):823-7
  • Makarov DV, Sanderson H, Partin AW, Epstein JI. Glea- son score 7 prostate cancer on needle biopsy: is the prog- nostic difference in Gleason scores 4 + 3 and 3 + 4 inde- pendent of the number of involved cores? J Urol. 2002 Jun;167(6):2440-42
  • Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer sta- ging nomograms (Partin Tables) for the new millennium. Urology. 2001 Dec;58(6):843-8
  • Nelson CP, Rubin MA, Strawderman M, Montie JE, Sanda MG. Preoperative parameters for predicting early prosta- te cancer recurrence after radical prostatectomy. Urology. 2002;59:740–745.
  • Gretzer MB, Epstein JI, Pound CR, Walsh PC, Partin AW. SubstratiŞcation of Stage T1C prostate cancer based on the probability of biochemical recurrence. Urology. 2002;60:1034–1039.
  • Dall’Era, M.A., et al., Active surveillance for the manage- ment of prostate cancer in a contemporary cohort. Cancer, 2008. 112(12): p. 2664-70.
  • Herman CM, Kattan MW, Ohori M, Scardino PT, Whee- ler TM. Primary Gleason pattern as a predictor of disease progression in gleason score 7 prostate cancer: a multivari- ate analysis of 823 men treated with radical prostatectomy. Am J Surg Pathol. 2001 May;25(5):657-60.
  • Lau WK, Blute ML, Bostwick DG, Weaver AL, Sebo TJ, Zincke H. Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: differences in outcome between primary Gleason grades 3 and 4. J Urol. 2001 Nov;166(5):1692-7.
  • Rasiah KK, Stricker PD, Haynes AM, Delprado W, Turner JJ, Golovsky D, Brenner PC, Kooner R, O’Neill GF, Grygi- el JJ, Sutherland RL, Henshall SM. Prognostic significance of Gleason pattern in patients with Gleason score 7 prosta- te carcinoma. Cancer. 2003 Dec 15;98(12):2560-5.
  • Wright JL, Salinas CA, Lin DW, Kolb S, Koopmeiners J, Feng Z, Stanford JL. Prostate cancer specific mortality and Gleason 7 disease differences in prostate cancer out- comes between cases with Gleason 4 + 3 and Gleason 3 + 4 tumors in a population based cohort. J Urol. 2009 Dec;182(6):2702-7.
  • Epstein JI. Gleason score 2-4 adenocarcinoma of the pros- tate on needle biopsy: a diagnosis that should not be made. Am J Surg Pathol. 2000 Apr;24(4):477-8.
  • Stark JR, Perner S, Stampfer MJ, Sinnott JA, Finn S, Eisens- tein AS, Ma J, Fiorentino M, Kurth T, Loda M, Giovan- nucci EL, Rubin MA, Mucci LA. Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol. 2009 Jul 20;27(21):3459-64.
  • Masieri L, Lanciotti M, Nesi G, Lanzi F, Tosi N, Minervi- ni A, Lapini A, Carini M, Serni S. Prognostic role of pe- rineural invasion in 239 consecutive patients with pat- hologically organ-confined prostate cancer. Urol Int. 2010;85(4):396-400.
  • Loeb S, Epstein JI, Humphreys EB, Walsh PC. Does perine- ural invasion on prostate biopsy predict adverse prostatec- tomy outcomes? BJU Int. 2010 Jun;105(11):1510-3.
  • A. Heidenreich (chairman), M. Bolla, S. Joniau,M.D. Ma- son, V. Matveev, N. Mottet, H-P. Schmid,T.H. van der Kwast, T. Wiegel, F. Zattoni. Guidelines on Prostate Can- cer. European Association of Urology 2011 p.28
  • Stephan C, Klaas M, Müller C, Schnorr D, Loening SA, Jung K Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update. Clin Chem. 2006 Jan;52(1):59-64.
  • Hara R, Jo Y, Fujii T, Kondo N, Yokoyoma T, Miyaji Y, Na- gai A. Optimal approach for prostate cancer detection as initial biopsy: prospective randomized study comparing transperineal versus transrectal systematic 12-core biopsy. Urology. 2008 Feb;71(2):191-5.
  • Takenaka A, Hara R, Ishimura T, Fujii T, Jo Y, Nagai A, Fujisawa M. A prospective randomized comparison of diagnostic efficacy between transperineal and transrec- tal 12-core prostate biopsy. Prostate Cancer Prostatic Dis. 2008;11(2):134-8.
  • Epstein JI, Herawi M. Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicio- us for carcinoma: implications for patient care. J Urol. 2006 Mar;175(3 Pt 1):820-34.
There are 26 citations in total.

Details

Primary Language Turkish
Journal Section Original Article
Authors

Sacit Nuri Görgel This is me

Yusuf Kürşad Özdamar This is me

Uğur Balcı This is me

Publication Date August 1, 2011
Published in Issue Year 2011 Volume: 6 Issue: 3

Cite

Vancouver Görgel SN, Özdamar YK, Balcı U. Gleason skoru 3+4 ve 4+3 prostat kanseri olgularında preoperatif klinikopatolojik ve radyografik bulguların karşılaştırılması. New J Urol. 2011;6(3):6-10.